WORLD TRADE ORGANIZATION

G/TBT/N/NZL/129

2 October 2023

(23-6605)

Page: 1/2

**Committee on Technical Barriers to Trade**

Original: English

## NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

| | |
|---|---|
| **1.** | **Notifying Member:** NEW ZEALAND<br><br>**If applicable, name of local government involved (Article 3.2 and 7.2):** |
| **2.** | **Agency responsible:**<br><br>Ministry for Health<br>PO Box 5013<br>Wellington 6140<br>New Zealand<br><br>**Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:**<br><br>TBT Enquiry Point of New Zealand<br>Ministry of Business, Innovation and Employment<br>Level 6, 15 Stout Street, Wellington 6011;<br>Email: wto@standards.govt.nz<br>Phone: (+64) 4 896 5711 |
| **3.** | **Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], 3.2 [ ], 7.2 [ ], other:** |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Medicinal cannabis, including products under HS Chapter 12 and 29. |
| **5.** | **Title, number of pages and language(s) of the notified document:** Guideline on the regulation of medicinal cannabis in New Zealand: Part 3 (Section 3.2.2)<br><br>Guideline on the Regulation of Therapeutic Products in New Zealand: Labelling of Medicines and Related Products (Section 2.2 and Figure A).; (33 page(s), in English), (19 page(s), in English) |
| **6.** | **Description of content:** Medicinal cannabis products supplied in New Zealand are required to meet the labelling requirements outlined in regulation 19 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. The Ministry of Health is proposing a technical amendment to regulation 19 to add a reference to the requirement for medicinal cannabis products to display a controlled drug classification statement on the label to align with the labelling of all other controlled drugs supplied as medicines in New Zealand. This requirement is already in place and enforced under the Misuse of Drugs Regulations 1977. The proposed change is a clarifying amendment and not a substantive change in regulation. The technical amendment will reflect the existing guidance issued in Section 3.2.2. of the 'Guideline on the regulation of medicinal cannabis in New Zealand: Part 3' and the 'Guideline on the Regulation of Therapeutic Products in New Zealand Part 5' Section 2.2 and Figure A. |

| | |
|---|---|
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** This technical update to the legislation is intended to clarify a requirement which already exists and is enforced.<br><br>The requirement for medicinal cannabis products to display a controlled drug classification statement ensures that there is transparency so participants in the supply chain are aware about how the product should be recorded, handled and stored. |
| **8.** | **Relevant documents:**<br><br>Guideline on the regulation of medicinal cannabis in New Zealand: Part 3<br><br>Guideline on the Regulation of Therapeutic Products in New Zealand: Labelling of Medicines and Related Products |
| **9.** | **Proposed date of adoption:** December 2023<br><br>**Proposed date of entry into force:** January 2024 |
| **10.** | **Final date for comments:** 60 days from notification |
| **11.** | **Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:** |